Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: Significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma

Ree, H. J.; Yang, Woo Ick; Kim, Chul Woo; Huh, Jooryung; Lee, Seung-Sook; Cho, Eun Yoon; Ko, Yong-Hyeh; Charney, Douglus

doi:10.1053/hupa.2001.27118

Cited by 45 publications

(38 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13,29 The Bcl6 expression pattern in FL is similar to that in normal follicles. 8,10 Its expression frequency has been reported high (94 to 100%) in FL. 8 In the present study, Bcl6 was positive in 71% of FL.…”

Section: Discussionmentioning

confidence: 99%

“…8,10 Its expression frequency has been reported high (94 to 100%) in FL. 8 In the present study, Bcl6 was positive in 71% of FL. The expression pattern of Bcl6 in FL was different to that in normal follicles.…”

Section: Discussionmentioning

confidence: 99%

“…CD10 and Bcl6 are regarded as reliable markers to identify germinal centre B-cell lymphoma, in particular FL. 8 Bcl2, an antiapoptosis protein, is expressed in follicles and is a phenotypic marker to differentiate FL from reactive follicular hyperplasia. CD10 and Bcl2 are expressed in most cases of FL but CD10-and Bcl2-negative cases do exist.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances

et al. 2005

View full text Add to dashboard Cite

JapanFollicular lymphomas (FL) are morphologically classified into grades 1, 2, 3a and 3b by the World Health Organization. Bcl2, Bcl6 and CD10 are phenotypic markers of FL while the Bcl2 t(14;18) and Bcl6 t(3q27) gene translocations are common genetic changes. However, to date, there has been no integrated analysis based on phenotype, grade and genotype from large numbers of FL cases. We graded 261 cases of FL and determined their phenotypes and gene alterations. According to the antigen markers and gene alterations of 147 cases, we classified FL into typical and the others types. The typical group, which includes 69% cases of FL, is characterized by low histological grade (grade 1, 2), coexpression of BCL2 and CD10 and Bcl2 gene translocation. The rest comprises a small part of low-grade FL without Bcl2 gene translocation and high-grade (grade 3a, 3b) FL. These FLs include some heterogeneous disease entities. They are characterized by high histological grade (87%), no definite expression of BCL2 or CD10 and several kinds of gene aberrances including Bcl2 translocation, Bcl6 translocation, Bcl2 amplification or other unknown gene abnormality. Our findings indicate that typical FL presents a homogeneous disease entity whereas the rest comprises heterogeneous diseases entities.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances

et al. 2005

View full text Add to dashboard Cite

show abstract

“…10 Both CD10 and bcl-6 are considered as germinal center markers while IRF-4 has been found expressed in plasma cells and a subset of cells in the apical light zone of the germinal center. 11,12 Other new prognostic markers have also been suggested in DLBCL such as p53 and bcl-2 expression; 10,[13][14][15][16][17][18] however, different studies have shown divergent results and the prognostic values of some of these markers is still not clear. 19 In DLBCL, many of the patients have an earlier history of a low-grade malignant lymphoma, especially follicular lymphoma, and these cases have been shown to be more similar to the ancestral lymphoma type on a molecular level.…”

mentioning

confidence: 99%

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

et al. 2005

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) has been shown to be comprised of at least two prognostic entities, depending on its resemblance to normal germinal center or activated B cells, using global gene expression profiling. Also, the expression patterns of bcl-6, CD10 and IRF-4 (also known as MUM1) have been suggested as alternative means of identifying the germinal-and nongerminal center (activated B-cell like) groups. In the present study, we evaluated by immunohistochemistry the expression patterns of CD10, bcl-6, IRF-4 and bcl-2 in a large material of 161 DLBCL patients. Using two different approaches, patients with germinal center phenotype displayed a significantly better survival than the nongerminal center group. Positive staining for bcl-6 or CD10 predicted for superior survival, while expression of IRF-4 alone showed no association with prognosis. Furthermore, expression of bcl-2 was associated with worse event-free survival and overall survival. In a multivariate analysis, a high international prognostic index score (3-5), non-GC phenotype and bcl-2 were independent adverse prognostic factors. Here we confirm the prognostic importance of determining the germinal-or nongerminal center phenotype in patients with DLBCL.

show abstract

“…Among hematopoietic cells, CD10 is expressed by immature B and T cells, by the germinal center B cells, by granulocytes, and by cells of a number of lymphoid malignancies (4,5,10,33). Regarding B-cell non-Hodgkin's lymphomas, CD10 protein is expressed in almost all Burkitt lymphomas, in most follicular B-cell lymphomas, and in a proportion of diffuse large B-cell lymphomas, whereas marginal zone/mucosa associated lymphoid tissue (MALT) lymphomas and mantle cell lymphomas are CD10 negative (10,24,(27)(28)(29)(30)(31)(32)(33)(34)(35).…”

mentioning

confidence: 99%

Increased Expression of the bcl6 and CD10 Proteins Is Associated with Increased Apoptosis and Proliferation in Diffuse Large B-Cell Lymphomas

et al. 2003

View full text Add to dashboard Cite

There is increasing evidence that bcl6 and CD10 expression may be related to apoptosis and cell cycle progression. Therefore, 79 cases of de novo diffuse large B-cell lymphomas were studied for the expression of bcl6 and CD10 proteins in relation to 1) the apoptotic index; 2) the proliferationassociated proteins Ki67, cyclin A, and cyclin B1; and 3) the expression of the bcl2, p53, Rb, p16, and p27 proteins. Expression of bcl6, CD10, and bcl2 proteins was found in 54/79 (68%), 28/79 (35%), and 47/74 (63%) cases, respectively. The bcl6/CD10 patterns were as follows: bcl6؉/CD10؉ (26 cases, 32%), bcl6؉/CD10-(28 cases, 33%), bcl6؊/CD10؊ (23 cases, 31%), and bcl6؊/CD10؉ (2 cases, 4%). Significant positive correlations were found between bcl6/Ki67 (r ‫؍‬ .328, P ‫؍‬ .003), bcl6/cyclin A (r ‫؍‬ .265, P ‫؍‬ .018), bcl6/apoptotic index (r ‫؍‬ .327, P ‫؍‬ .010), CD10/Ki67 (r ‫؍‬ .296, P ‫؍‬ .008), and CD10/ apoptotic index (r ‫؍‬ .397, P ‫؍‬ .001). In addition, high expression of bcl6 showed significant correlation with negative (null/low) bcl2 expression ( 2 test, P ‫؍‬ .002). The above findings indicate that increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. The association between increased bcl6 expression and enhanced apoptosis might be due, at least in part, to the null/low bcl2 expression because previous in vitro data showed that bcl6 overexpression induces apoptosis accompanied by bcl2 and bcl-xl downregulation. Moreover, significant correlation was found between increased apoptotic index and the bcl6؉/CD10؉ pattern (t test: P ‫؍‬ .014, MannWhitney test: P ‫؍‬ .046). This finding and the positive correlation of the apoptotic index with bcl6 and CD10 expression may be related to previous results showing that the expression of these proteins has favorable effects on the clinical outcome of diffuse large B-cell lymphomas.

show abstract

Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: Significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma

Cited by 45 publications

References 42 publications

Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances

Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

Increased Expression of the bcl6 and CD10 Proteins Is Associated with Increased Apoptosis and Proliferation in Diffuse Large B-Cell Lymphomas

Contact Info

Product

Resources

About